Articles from Sage Therapeutics

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Sage Therapeutics, Inc. (NASDAQSAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA.

Sage Therapeutics announced today topline results from the Phase 2 SURVEYOR Study. The study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo.

Sage Therapeutics, Inc. (NASDAQSAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor conferences in May:

Sage Therapeutics (NASDAQSAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage’s current and emerging product pipeline through all stages of development.

Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the launch of SageCitizen – a corporate social impact effort that activates and amplifies Sage’s long-term commitment to People, Patients, Planet and Community.

Sage Therapeutics (NASDAQSAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi as Chief Commercial Officer. In his new role, Mr. Benecchi will lead Sage’s global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence.

Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast this morning, June 15, 2021 at 8:00 a.m. ET to review topline results from the Phase 3 WATERFALL Study evaluating zuranolone for major depressive disorder.

Sage Therapeutics (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced participation in the first-ever Mental Health Action Day, on May 20, convened by MTV Entertainment Group and including more than 1,300 leading brands, nonprofits, government agencies and cultural leaders. Mental Health Action Day is an open-source movement of brands, organizations, and cultural leaders to turn mental health awareness into the appropriate mental health action. On May 20 and throughout the month of May, Sage will be focusing on inspiring employees to take mental health action for themselves, their friends, family, or for their community. “Sageans” are encouraged to break the stigma by talking about mental health, understanding mental health and the impact it can have, and importantly asking for help when needed, even in the workplace.

Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host the first Sage Science Spotlight webcast focused on an in-depth review of SAGE-718.